PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM

• ◆

  6 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM 1985-08-22 → present
2. PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM LIMITED 1969-02-26 → 1985-08-22

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The board has reviewed our financial position and believes that there are sufficient resources to manage any operational or financial risks. We expect that we have adequate resources to continue operating for the foreseeable future and no material uncertainties have been identified. Trustees have designated surplus reserves above the upper threshold of our policy to support delivery of our strategic plan.”

Group structure

1. PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM · parent
   1. Parkinson's UK Sales Limited 100% · England and Wales · Trading element of fundraising events and sale of daily living aids
   2. Parkinson's Research Ventures Limited 100% · England and Wales · Commercial aspects of forming partnerships to fund research into better treatments and a cure for Parkinson's
   3. Vivifi Biotech Limited 100% · England and Wales · Develop a potential new trial of Glial Cell-Line Derived Neurotrophic Factor
   4. Keapstone Therapeutics Limited 40% · UK · Research and experimental development on biotechnology
   5. NRG Therapeutics Limited 24.1% · UK · Research and experimental development on biotechnology

Significant events

• “Key events included the London Marathon and our Walk for Parkinson's series, with the latter surpassing the £1m mark for the first time.”
• “We embarked on a major funding partnership with the Gatsby Foundation, pledging £4m to support Landmark, our three-year research programme to unlock a cure for Parkinson's.”
• “Corporate partnerships had an award-winning year at the annual Third Sector Business Charity Awards, with Everyone Active winning the 2024 Sport, Travel and Leisure award.”
• “In September 2024, we launched our pioneering, three-year Landmark research programme, using big data to accelerate new treatments for the condition.”
• “In September 2024, we moved to our new London location, 50 Broadway.”
• “In February 2024, the board took the decision to enable an orderly close-down of Vivifi Biotech Limited.”
• “In May 2025, the directors of Parkinson's Research Ventures Limited were made aware that Lucy Therapeutics was to discontinue business and go into liquidation.”
• “In April 2025, the directors of Parkinson's Research Ventures Limited were made aware that Acurex was the subject of a legal action.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

16

last 12 months

Capital events

0

last 24 months

Officers appointed

6

last 12 months

Officers resigned

6

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -2.2%

  £556,000 → £544,000

• Cash

  +35.9%

  £11,796,000 → £16,036,000

• Net assets

  -13.7%

  £65,093,000 → £56,189,000

• Employees

  +23.5%

  392 → 484

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers